WEST Search History

DATE: Thursday, December 04, 2003

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR		
L74	L73 and particulate	19	L74
L73	L72 and biodegradable	68	L73
L72	L71 and lactide	89	L72
L71	L70 and vaccine	114	L71
L70	L69 and pylori	178	L70
L69	helicobacter and glycolide	190	L69
L68	L66 and glycolide	3	L68
L67	L66 and polymer	8	L67
L66	L62 and vaccine	50	L66
L65	L62 and polymer	23	L65
L64	L62 and lactide	6	L64
L63	L62 and poly lactide	9181	L63
L62	H.pylori	133	L62
L61	L60 and IB-367	2	L61
L60	L59 and ventilation	37	L60
L59	VAP	1377	L59
L58	IB-367 and VAP	2	L58
L57	IB-367	12	L57
L56	L55 and peroxide	5	L56
L55	L53 and surfactant	126	L55
L54	L53 and bioactive	5	L54
L53	L52 and tocopherol	126	L53
L52	L51 and ethanol	130	L52
L51	L50 and stearic	136	L51
L50	L46 and iodine	329	L50
L49	L48 and ethanol	9	L49
L48	L46 and capric	16	L48
L47	L46 and phosphate ester	663462	L47
L46	L45 and bovine	956	L46
L45	L42 and mastitis	2044	L45
L44	L43 and l42	32	L44

Generate Collection | Print

Search Results - Record(s) 11 through 19 of 19 returned.

☑ 11. 20020197321 . 29 Apr 02. 26 Dec 02. Solid dispersing vaccine composition for oral delivery. Seager, Harry. 424/486; A61K009/14.

☑ 12. 20020136776 . 28 Sep 01. 26 Sep 02. Microparticle compositions and methods for the manufacture thereof. Fang, Jia-Hwa, et al. 424/501; 424/70.11 424/94.1 514/44 A61K048/00 A61K038/43 A61K007/11 A61K009/50 A61K007/06.

☐ 13. 20020025329 . 20 Aug 01. 28 Feb 02. Use of microparticles combined with submicron oil-in-water emulsions. O'Hagan, Derek, et al. 424/278.1; 424/204.1 424/228.1 424/280.1 424/283.1 424/497 424/70.11 424/70.19 424/70.9 A61K009/16 A61K009/50 A61K007/06 A61K007/075 A61K039/12 A61K045/00 A61K047/00.

☑ 14. 6623764 . 31 Aug 99; 23 Sep 03. Biodegradable targetable microparticle delivery system. Sokoll; Kenneth K., et al. 424/501; 424/78.37 528/318 528/329.1. A61K009/16 A61K047/34 C08G063/08.

☐ 15. 6534064 . 10 Oct 00; 18 Mar 03. Stabilized protein particles for inducing cellular immune responses. O'Hagan; Derek, et al. 424/205.1; 424/199.1 424/204.1 424/207.1 424/208.1 424/225.1 424/228.1 424/229.1 424/70.14 424/70.16 424/9.34 435/8 518/726. A61K039/12 A61K039/29 C07B063/06 C12Q001/70 C07C047/06.

☐ 16. 6514503 . 09 Jul 98; 04 Feb 03. Antigen delivery system. Gizurarson; Sveinbjorn, et al. 424/278.1; 424/184.1 424/234.1 514/2. A61K045/00 A61K047/00 A61K039/02.

☐ 17. 6458370 . 20 Aug 01; 01 Oct 02. Use of microparticles combined with submicron oil-in-water emulsions. O'Hagan; Derek, et al. 424/278.1; 424/204.1 424/228.1 424/283.1 424/70.11 424/70.19 435/4 435/5 435/6. A61K039/00 A61K045/00 C12Q001/00 C12Q001/70 C12Q001/68.

☑ 18. 6306405 . 02 May 00; 23 Oct 01. Use of microparticles combined with submicron oil-in-water emulsions. O'Hagan; Derek, et al. 424/278.1; 424/204.1 424/228.1 424/283.1. A61K045/00 A61K039/12 A61K039/29.

☑ 19. 6086901 . 29 Jan 98; 11 Jul 00. Use of microparticles combined with submicron oil-in-water emulsions. O'Hagan; Derek, et al. 424/283.1; 424/204.1 424/228.1 424/278.1 424/497 424/70.11 424/70.19. A61K039/29 A61K007/08 A61K045/00 A61K047/44.

Generate Collection | Print

Terms	Documents
L73 and particulate	19

Previous Page Next Page

Generate Collection | Print

Search Results - Record(s) 1 through 10 of 19 returned.

☑ 1. 20030211122 . 12 Jun 03. 13 Nov 03. Mucosal microparticle conjugate vaccine. Sjoholm, Ingvar, et al. 424/258.1; A61K039/112.

☐ 2. 20030170273 . 03 Oct 02. 11 Sep 03. Adjuvant compositions. O'Hagan, Derek, et al. 424/225.1; 424/130.1 424/199.1 435/6 514/44 A61K048/00 A61K039/395 C12Q001/68 A61K031/70 A01N043/04 A61K039/12 A61K039/29.

☐ 3. 20030138453 . 28 Sep 01. 24 Jul 03. Microparticles for delivery of heterologous nucleic acids. O'Hagan, Derek, et al. 424/199.1; 435/235.1 435/320.1 435/325 435/343 435/5 C12Q001/70 A61K039/12 C12N007/00 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N005/00 C12N005/02 C12N005/06 C12N005/16.

☐ 4. 20030104067 . 08 Jan 03. 05 Jun 03. Method of obtaining cellular immune responses from proteins. O' Hagan, Derek, et al. 424/490; 424/186.1 424/188.1 424/189.1 A61K039/21 A61K039/29 A61K009/16 A61K009/50.

☐ 5. 20030099659 . 12 Jul 02. 29 May 03. Antigen delivery system. Gizurarson, Sveinbjorn, et al. 424/184.1; A61K039/00.

☐ 6. 20030082213 . 02 Aug 02. 01 May 03. Use of microparticles combined with submicron oil-in-water emulsions. O'Hagan, Derek, et al. 424/278.1; 424/204.1 424/228.1 424/283.1 424/70.11 424/70.19 A61K007/06 A61K007/075 A61K039/12 A61K045/00 A61K047/44 A61K007/11 A61K007/08 A61K039/29 A61K047/00.

☐ 7. 20030078396 . 06 Nov 01. 24 Apr 03. Compositions and methods for the detection, diagnosis and therapy of hematological malignancies. Gaiger, Alexander, et al. 536/23.1; C07H021/02 C07H021/04.

☑ 8. 20030072768 . 12 Nov 02. 17 Apr 03. Method to enhance an immune response of nucleic acid vaccination. Dalemans, Wilfried, et al. 424/185.1; 424/486 514/44 A61K048/00 A61K039/38 A61K039/00 A61K009/14.

☐ 9. 20030072764 . 05 Apr 02. 17 Apr 03. Mucosal boosting following parenteral priming. O'Hagan, Derek. 424/184.1; A61K039/00.

☐ 10. 20020198362 . 01 Mar 01. 26 Dec 02. Compositions and methods for the detection, diagnosis and therapy of hematological malignancies. Gaiger, Alexander, et al. 530/350; 435/320.1 435/325 435/6 435/69.1 536/23.1 C07K014/435 C12Q001/68 C07H021/04 C12P021/02 C12N005/06.

Generate Collection | Print

Terms	Documents
L73 and particulate	19

Previous Page Next Page

Generate Collection

L74: Entry 1 of 19 File: PGPB Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211122
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030211122 A1

TITLE: Mucosal microparticle conjugate vaccine

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sjoholm, Ingvar	Uppsala		SE	
Wikingsson, Lena Degling	Spanga		SE	

US-CL-CURRENT: 424/258.1

CLAIMS:

1. Mucosal microparticle conjugate vaccine against a certain pathogenic microorganism, which comprises, as an immunizing component, a T-cell activating amount of protection-generating antigens derived from said microorganism conjugated, possibly via a linker, to biodegradable microparticles.

2. Vaccine according to claim 1, wherein the biodegradable microparticles are starch particles, including cross-linked starch particles.

3. Vaccine according to claim 2, wherein the cross-linked starch particles are polyacryl starch microparticles.

4. Vaccine according to any one of claims 1-3, wherein the mucosal vaccine is an oral vaccine.

5. Vaccine according to any one of claims 1-4, wherein the pathogenic microorganism is an intracellular pathogenic microorganism.

6. Vaccine according to claim 5, wherein said intracellular pathogenic microorganism is selected from the group consisting of Mycobacterium tuberculosis and Salmonella enteritidis.

7. Method of inducing protective immunity against a certain pathogenic microorganism in a mammal, including man, comprising mucosal administration to said mammal of a T-cell activating amount of protection-generating antigens derived from said microorganism conjugated, possibly via a linker, to biodegradable microparticles, as an immunizing component.

8. Method according to claim 7, wherein the mucosal administration is oral administration and the protection-generating antigens derived from said microorganism are secreted proteins from Mycobacterium tuberculosis or Salmonella enteritidis

9. Use of protection-generating antigens derived from a certain pathogenic microorganism conjugated, possibly via a linker, to biodegradable microparticles for the production of a mucosal microparticle conjugate vaccine against said certain pathogen.

10. Use according to claim 7, wherein the mucosal vaccine is an oral vaccine, said antigens derive from Mycobacterium tuberculosis or Salmonella enteritidis, and the biodegradable microparticles are starch particles, including cross-linked starch particles and polyacryl starch microparticles.

Generate Collection

L74: Entry 1 of 19 File: PGPB Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211122
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030211122 A1

TITLE: Mucosal microparticle conjugate vaccine

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sjoholm, Ingvar	Uppsala		SE	
Wikingsson, Lena Degling	Spanga		SE	

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	COUNTRY	TYPE CODE
INNOVENTUS PROJECT AB				03

APPL-NO: 10/ 459525 [PALM]
DATE FILED: June 12, 2003

RELATED-US-APPL-DATA:
Application 10/459525 is a division-of US application 09/623046, filed November 9, 2000, PENDING
Application 09/623046 is a a-371-of-international WO application PC/T/SE99/00277, filed February 26, 1999, UNKNOWN

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	DOC-ID	APPL-DATE
SE	9800615-8	1998SE-9800615-8	February 27, 1998

INT-CL: [07] A61 K 39/112

US-CL-PUBLISHED: 424/258.1
US-CL-CURRENT: 424/258.1

ABSTRACT:

Mucosal, particularly oral, microparticle conjugate vaccines against certain pathogenic microorganisms, especially intracellular pathogenic microorganisms, are disclosed. An immunizing component of such a vaccine comprises protection-generating antigens derived from a certain pathogenic microorganism, such as Mycobacterium tuberculosis or Salmonella enteritidis, conjugated, possibly via a linker, to biodegradable microparticles, particularly starch microparticles, such as cross-linked starch microparticles, e.g. polyacryl starch microparticles. Further, a method of inducing protective immunity against a certain pathogenic microorganism in a mammal, and the use of protection-generating antigens derived from a certain pathogenic microorganism conjugated, possibly via a linker to biodegradable microparticles for the production of a mucosal microparticle conjugate vaccine are described.

Generate Collection | Print

Search Results - Record(s) 1 through 6 of 6 returned.

1. 20030049698 . 08 Oct 02. 13 Mar 03. Diagnosis and treatment of gastrointestinal disease. Wang, Timothy C.. 435/7.21; 435/7.32 G01N033/567 G01N033/554 G01N033/569.

2. 20020146423 . 23 Dec 97. 10 Oct 02. PROTECTIVE HELICOBACTER ANTIGENS. DOIDGE, CHRISTOPHER VINCENT, et al. 424/184.1; A61K039/00 A61K039/38.

3. 20020122794 . 09 Aug 96. 05 Sep 02. ANTIGENIC PREPARATION FOR TREATMENT OR PREVENTION OF HELICOBACTER INFECTION. DOIDGE, CHRISTOPHER VINCENT. 424/130.1; A61K039/395.

4. 6630582 . 07 Jan 98; 07 Oct 03. Treatment and prevention of helicobacter infection. Doidge; Christopher V., et al. 536/23.6; 424/234.1 424/93.2 435/192 435/7.32. C07H021/04.

5. 6468545 . 20 Oct 99; 22 Oct 02. Treatment and prevention of helicobacter infection. Doidge; Christopher V., et al. 424/234.1; 435/252.1 435/34 435/69.1 536/23.4 536/23.5. A61K039/02.

6. 6129923 . 29 Oct 98; 10 Oct 00. Treatment of H. pylori associated gastroduodenal disease. Doidge; Christopher Vincent, et al. 424/234.1; 424/194.1 536/23.1. A61K039/02.

Generate Collection | Print

Terms	Documents
L62 and lactide	6

Previous Page Next Page

Generate Collection | Print

Search Results - Record(s) 1 through 10 of 23 returned.

1. 20030162691. 10 Mar 03. 28 Aug 03. Novel antimicrobial therapies. Kornberg, Arthur. 514/1; 435/252.3 A61K031/00 C12N001/21.

2. 20030113338. 27 Apr 99. 19 Jun 03. IMMUNOGENIC DETOXIFIED MUTANT E. COLI LT-A TOXIN. PIZZA, MARIAGRAZIA, et al. 424/184.1; 424/265.1 514/2 530/350 A61K039/00 A01N037/18 C07K001/00.

3. 20030049698. 08 Oct 02. 13 Mar 03. Diagnosis and treatment of gastrointestinal disease. Wang, Timothy C.. 435/7.21; 435/7.32 G01N033/567 G01N033/554 G01N033/569.

4. 20020107368. 06 Dec 00. 08 Aug 02. Helicobacter proteins, gene sequences and uses thereof. Tian, Jing-Hui, et al. 530/388.4; 424/190.1 530/350 536/23.7 A61K031/70 C07H021/04 C07K001/00 C07K014/00 C07K017/00 C07K016/00 C12P021/08.

5. 20020090631. 14 Nov 01. 11 Jul 02. Method for predicting protein binding from primary structure data. Gough, David A., et al. 435/6; 435/7.1 702/19 702/20 C12Q001/68 G01N033/53 G06F019/00 G01N033/48 G01N033/50.

6. 20020081686. 28 Jun 01. 27 Jun 02. Novel antimicrobial therapies. Kornberg, Arthur. 435/184; 424/93.4 424/93.47 424/93.48 435/212 C12N009/99 C12N009/48 A01N063/00.

7. 20020051819. 15 Jun 01. 02 May 02. Peptides, compositions and methods for the treatment of burkholderia cepacia. Kuhner, Carla H., et al. 424/484; 424/486 424/488 514/17 A61K009/14 A61K038/08.

8. 20020045195. 12 Oct 01. 18 Apr 02. Method for the visual detection of specific antibodies in human serum by the use of lateral flow assays. Hubscher, Thomas T., et al. 435/7.9; 435/287.2 436/514 G01N033/53 G01N033/542 C12M001/34 G01N033/558.

9. 6610504. 10 Apr 00; 26 Aug 03. Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase. Yuan; Chong-Sheng. 435/15; 435/18. C12Q001/48 C12Q001/34.

10. 6585975. 01 Nov 99; 01 Jul 03. Use of Salmonella vectors for vaccination against helicobacter infection. Kleanthous; Harold, et al. 424/200.1; 424/234.1 435/6 435/69.1 514/44 536/23.5. A61K039/02.

Generate Collection | Print

Terms	Documents
L62 and polymer	23

Previous Page Next Page

Generate Collection | Print

Search Results - Record(s) 21 through 23 of 23 returned.

☐ 21. CN 1397283 A WO 9638186 A1 AU 9657557 A AU 701974 B BR 9609166 A CN 1186436 A. Novel chemotherapeutic compsns. to treat cancer - comprise polymeric and/or copolymeric compsns. to treat also gastrointestinal disease, diarrhoea, increases weight in humans, animals and birds. MELROSE, G J H. A23K001/16 A61K031/765 A61P035/00 C08G077/42 C08L029/00 C08L029/14 C08L033/02.

☑ 22. WO 9605822 A1 US 5534544 A. Use of surfactants and emulsifying agents to inhibit Helicobacter pylori - and treatment of infection by sequential admin of antibiotic then surfactant or emulsifying agent free of calcium, magnesium, aluminium or silicon ions. KANE, A V, et al. A61K031/23 A61K031/34.

☐ 23. WO 9532414 A1. Strip device for detection of antibody analytes - using a receptor specific for a conserved region of the antibody conjugated to a directly detectable label. GOVINDARAJAN, A G, et al. G01N021/00 G01N033/53 G01N033/543 G01N033/544 G01N033/552 G01N033/553.

Generate Collection | Print

Terms	Documents
L62 and polymer	23

Previous Page Next Page

Generate Collection | Print

Search Results - Record(s) 3 through 12 of 23 returned.

3. 20030049698 . 08 Oct 02. 13 Mar 03. Diagnosis and treatment of gastrointestinal disease. Wang, Timothy C.. 435/7.21; 435/7.32 G01N033/567 G01N033/554 G01N033/569.

4. 20020107368 . 06 Dec 00. 08 Aug 02. Helicobacter proteins, gene sequences and uses thereof. Tian, Jing-Hui, et al. 530/388.4; 424/190.1 530/350 536/23.7 A61K031/70 C07H021/04 C07K001/00 C07K014/00 C07K017/00 C07K016/00 C12P021/08.

5. 20020090631 . 14 Nov 01. 11 Jul 02. Method for predicting protein binding from primary structure data. Gough, David A., et al. 435/6; 435/7.1 702/19 702/20 C12Q001/68 G01N033/53 G06F019/00 G01N033/48 G01N033/50.

6. 20020081686 . 28 Jun 01. 27 Jun 02. Novel antimicrobial therapies. Kornberg, Arthur. 435/184; 424/93.4 424/93.47 424/93.48 435/212 C12N009/99 C12N009/48 A01N063/00.

7. 20020051819 . 15 Jun 01. 02 May 02. Peptides, compositions and methods for the treatment of burkholderia cepacia. Kuhner, Carla H., et al. 424/484; 424/486 424/488 514/17 A61K009/14 A61K038/08.

8. 20020045195 . 12 Oct 01. 18 Apr 02. Method for the visual detection of specific antibodies in human serum by the use of lateral flow assays. Hubscher, Thomas T., et al. 435/7.9; 435/287.2 436/514 G01N033/53 G01N033/542 C12M001/34 G01N033/558.

9. 6610504 . 10 Apr 00; 26 Aug 03. Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase. Yuan; Chong-Sheng. 435/15; 435/18. C12Q001/48 C12Q001/34.

10. 6585975 . 01 Nov 99; 01 Jul 03. Use of Salmonella vectors for vaccination against helicobacter infection. Kleanthous; Harold, et al. 424/200.1; 424/234.1 435/6 435/69.1 514/44 536/23.5. A61K039/02.

11. 6551795 . 18 Feb 99; 22 Apr 03. Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics. Rubenfield; Marc J., et al. 435/69.1; 435/253.3 435/320.1 435/325 435/6 536/23.1 536/23.7. C12P021/06 C12N015/00 C07H021/04.

12. 6528325 . 13 Oct 00; 04 Mar 03. Method for the visual detection of specific antibodies in human serum by the use of lateral flow assays. Hubscher; Thomas T., et al. 436/518; 422/56 422/58 435/287.2 435/287.7 435/7.1 435/7.94 436/513 436/514. G01N033/543.

Generate Collection | Print

Terms	Documents
L62 and polymer	23